Thymosin Alpha-1 Dosage Guide: Research Protocols, Timing & Reconstitution

Standard Dosage Range

Research dosing range: 0.5–1.6 mg per dose, 1-3 times per week

Educational reference only

These dosage ranges are derived from preclinical research and community protocols. No human clinical dose-ranging trials have established therapeutic doses for most research peptides. Always consult a qualified healthcare provider before starting any peptide protocol.

Dosage by Use Case

Hepatitis B/C (as Zadaxin)

1.6 mg2× weekly

Duration

6–12 months

Standard pharmaceutical protocol for chronic hepatitis B and C. Monitor liver enzymes regularly.

Adjunct Cancer Immunotherapy

0.5–1.0 mg2–3× weekly

Duration

4–12 weeks

Administered subcutaneously in conjunction with chemotherapy or checkpoint inhibitors. Cycles can be repeated after a 4-week break. Consult with an oncologist.

Immune Support (immunocompromised)

0.5–1.0 mg1–2× weekly

Duration

4–8 weeks

For individuals with weakened immune systems due to illness or medical treatment. Monitor immune markers (e.g., CBC, lymphocyte subsets).

COVID-19 Adjunct Therapy

0.8-1.6 mg1-2x weekly

Duration

2-4 weeks

Used in clinical trials as an adjunct to standard care in severe COVID-19 cases. Requires close medical supervision.

Vaccine Response Enhancement

0.5–1.0 mg1-2x weekly

Duration

2-4 weeks

Administered around the time of vaccination to enhance immune response, especially in elderly or immunocompromised individuals. Consult with your physician.

Timing & Frequency

Administer subcutaneous injections at a consistent time of day. For vaccine response enhancement, begin dosing 1-2 weeks before vaccination and continue for 1-2 weeks after.

Cycle Guidance

Cycles typically range from 4 to 12 weeks, followed by a break of at least 4 weeks. Long-term continuous use is not well-studied. Monitor immune function and overall health regularly.

Reconstitution Reference

Quick reference for reconstituting Thymosin Alpha-1. For custom vial sizes and concentrations, use the Reconstitution Calculator.

Common Vial Size	Typically 1.6 mg per vial
BAC Water Volume	1 mL bacteriostatic water for 1.6 mg/mL concentration
Concentration & Draw	At 1.6 mg/mL: 0.1 mg = 0.0625 mL (6.25 units on a 100-unit insulin syringe)
Storage	Refrigerate at 2–8°C after reconstitution. Keep lyophilized powder refrigerated or frozen.
Stability	Reconstituted solution stable up to 7 days refrigerated. Lyophilized powder stable 24 months frozen per manufacturer specifications.

Use the Reconstitution Calculator → for precise injection volumes based on your exact vial size, water volume, and desired dose.

Frequently Asked Questions

What is the standard Thymosin Alpha-1 dosage for hepatitis B?

The typical dosage for chronic hepatitis B, as approved for Zadaxin, is 1.6 mg administered subcutaneously twice per week for 6-12 months.

How is Thymosin Alpha-1 administered?

Thymosin Alpha-1 is administered via subcutaneous injection. Follow your healthcare provider’s instructions for proper injection technique and site rotation.

Can Thymosin Alpha-1 be used long-term?

Long-term safety and efficacy data for Thymosin Alpha-1 are limited beyond the approved indications. Consult with your physician to determine the appropriate duration of treatment for your specific condition.

What are the side effects of Thymosin Alpha-1?

Common side effects include injection site reactions (redness, swelling, pain), mild fatigue, and flu-like symptoms. Rare but more serious side effects may include autoimmune flares. Report any unusual or concerning symptoms to your healthcare provider immediately.

Is Thymosin Alpha-1 legal?

Thymosin Alpha-1 is approved as a pharmaceutical drug (Zadaxin) in over 35 countries for specific medical conditions. Its use for other purposes may be subject to regulatory restrictions. Check with your local regulations and consult with a licensed healthcare provider.